Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years

Hely, Mariese A., Morris, John G.L., Reid, Wayne G.J., Trafficante, Robert·2005·Movement Disorders
DOI 10.1002/mds.20324

Cited by (1,000)

Items 701–800 of 1,000

  1. Dementia-Free Survival and Risk Factors for Dementia in a Hospital-Based Korean Parkinson's Disease Cohort
    Su Yun Lee, Hyun-Ju Ryu, Jeong-Wook Seo, Maeng Seok Noh, Sang‐Myung Cheon, Jae Woo Kim · 2017 · Journal of Clinical Neurology
  2. Time-course of decline in different cognitive domains in Parkinson’s disease: a retrospective study
    Christian F. Altmann, Kristian Trubelja, David Emmans, Wolfgang H. Jost · 2021 · Journal of Neural Transmission
  3. The Profound Impact of Gastrointestinal Stasis on Levodopa Response in Parkinson's Disease
    Laura Williams, Jane Griffith, Sophie E. Waller, Vu Kwan, Victor S.C. Fung · 2022 · Movement Disorders Clinical Practice
  4. Evaluation of the effects of the mGlu2/3 antagonist LY341495 on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
    Stephen G. Nuara, Jim C. Gourdon, Philippe Huot · 2022 · Pharmacological Reports
  5. An approach to acute clinical deterioration in patients with late-stage Parkinson’s disease
    Laura Williams, Jessica X. Qiu, Sophie E. Waller, David S Tsui, Jane Griffith, Victor S.C. Fung · 2022 · Australian Journal of General Practice
  6. How I treat Parkinson's disease
    Egberto Reis Barbosa, João Carlos Papaterra Limongi, Hsin Fen Chien, Pedro Barbosa, Marcela Reuter Carréra Torres · 2022 · Arquivos de Neuro-Psiquiatria
  7. Anti-parkinsonian effect of the mGlu2 positive allosteric modulator LY-487,379 as monotherapy and adjunct to a low L-DOPA dose in the MPTP-lesioned marmoset
    Imane Frouni, Cynthia Kwan, Sébastien Belliveau, Adjia Hamadjida, Dominique Bédard, Stephen G. Nuara, Jim C. Gourdon, Philippe Huot · 2022 · European Journal of Pharmacology
  8. Dementia after DBS Surgery: A Case Report and Literature Review
    Irena Rektorová, Zuzana Hummelová, M. Balaz · 2011 · Parkinson s Disease
  9. Basic science in Parkinson’s disease: its impact on clinical practice
    Jörg Bernhard Schulz, Manfred Gerlach, Gabriele Gille, Wilfried Kuhn, Martina Müngersdorf, Peter Franz Riederer, Martin Südmeyer, Albert Ludolph · 2011 · Journal of Neurology
  10. Advanced Parkinson's disease: Clinical characteristics and treatment. Part II
    Jaime Kulisevsky, M. R. Luquín, José Matías Arbelo, Juan Andrés Burguera, F. Carrillo, A. Castro, J. Chacón, Pedro Ruiz, E. Lezcano, Pablo Mir et al. · 2013 · Neurología (English Edition)
  11. Aktivierende Therapien bei Parkinson-Syndromen
    Frauke E. Schroeteler, Urban M. Fietzek, Kerstin Ziegler, Andrés Ceballos-Baumann · 2018 · Nervenheilkunde
  12. The impact of depression on survival of Parkinson's disease patients: a five-year study
    Cláudia Débora Silberman, Cláudia Soares Rodrigues, Eliasz Engelhardt, Jerson Laks · 2013 · Jornal Brasileiro de Psiquiatria
  13. Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat
    Cynthia Kwan, Imane Frouni, Dominique Bédard, Adjia Hamadjida, Philippe Huot · 2020 · Behavioural Pharmacology
  14. Maladie de Parkinson idiopathique : aspects cliniques, diagnostiques et thérapeutiques
    François Viallet, Dominique Gayraud, Bernadette Bonnefoi, Laurent Renié, R. Aurenty · 2010 · Encyclopédie médico-chirurgicale. Neurologie
  15. Pushing or pulling to predict falls in Parkinson disease?
    Chris J. Hass, Bastiaan R. Bloem, Michael S. Okun · 2008 · Nature Clinical Practice Neurology
  16. Parkinson's disease: treatment and non-motor features
    Graeme J.A. Macphee, David Alan Stewart · 2012 · Reviews in Clinical Gerontology
  17. Medical Management of Advanced Parkinson's Disease
    John L. Goudreau · 2006 · Clinics in Geriatric Medicine
  18. Parkinson’s Disease: Basic Pathomechanisms and a Clinical Overview
    Alastair John Noyce, Rina Bandopadhyay · 2017 · Advances in neurobiology
  19. The Dopaminergic and Non‐Dopaminergic Features of Parkinson's Disease
    C. Warren Olanow, Fabrizio Stocchi, Anthony Edward Lang · 2011 · Parkinson s Disease
  20. Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?
    Mohammed Alsalmi, Jawad Al‐Kassmy, Woojin Kang, Michael Palayew, Philippe Huot · 2023 · Expert Opinion on Pharmacotherapy
  21. Nano-structured strategies in combatting neurodegeneration
    Mani Iyer Prasanth, Anjali R. Mallya, William Chi Shing Cho, Deepa Mundekkad · 2025 · Frontiers in Bioengineering and Biotechnology
  22. Predicting Depression in Parkinson’s Disease Using Commonly Available PD Questionnaires
    Emanuele Camerucci, Kelly E. Lyons, Rajesh Pahwa · 2024 · Journal of Clinical Medicine
  23. The Role of the Claustrum in Parkinson’s Disease and Vascular Parkinsonism: A Matter of Network?
    Marialuisa Zedde, R. Quatrale, Gianni Cossu, Massimo Del Sette, Rosario Pascarella · 2025 · Life
  24. Use of catechol‐O‐methyltransferase inhibition to minimize L‐3,4‐dihydroxyphenylalanine‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned macaque
    Philippe Huot, Tom H. Johnston, Tessa Snoeren, James B. Koprich, Michael P. Hill, Susan Helen Fox, Jonathan M. Brotchie · 2013 · European Journal of Neuroscience
  25. A Practical Consensus Guideline for the Integrative Treatment of Parkinson's Disease in Shanghai, China
    Weidong Pan, Jun Liu, Xiangjun Chen, Qiudong Wang, Yun‐Cheng Wu, Yu Bai, Yi Liu, Wentao Li, Wenwei Li, Can‐Xing Yuan et al. · 2015 · Integrative Medicine International
  26. Progresión clínica de la enfermedad de Parkinson: análisis retrospectivo en un consultorio especializado en trastornos del movimiento
    Sergio Daniel Scollo, Franchello Emanuel, Delfina Crimi, Sergio Alejandro Rodriguez-Quiroga, Corina Christie, Vanina Díaz-Arangunde, Tomoko Arakaki, Nélida Garretto · 2016 · Neurología Argentina
  27. Dopamine D3 receptor ligand suppresses the expression of levodopa-induced dyskinesia in nonhuman primate model of parkinson's disease
    Thomas T Oh, Elyas S. Daadi, Jeffrey J. Kim, Etienne W. Daadi, Peng‐Jen Chen, Gourav Roy-Choudhury, Jonathan A. Bohmann, Benjamin E. Blass, Marcel M. Daadi · 2021 · Experimental Neurology
  28. Combination of Stem Cells with Chinese Herbs for Secondary Depression in Neurodegenerative Diseases Based on Traditional Chinese Medicine Theories
    Jiahao Feng, Li Liao, Fangfang Xu, Lin Zhang, Jun Zhang · 2022 · Evidence-based Complementary and Alternative Medicine
  29. Impact of affective and cognitive impairments on quality of life in patients with early stages of Parkinson’s disease
    Marina Romanovna Nodel, Gyulnara Zh. Mahmudova, Ilmar Nikolas V. Niinoja, Dmitry V. Romanov · 2022 · Russian neurological Journal
  30. Investigation of PRKN Mutations in Levodopa-Induced Dyskinesia in Parkinson’s Disease Treatment
    Ana Gabrielle Bispo, Caio Santos Silva, Camille Sena-dos-Santos, Dafne Dalledone Moura, Brenda Hanae Bentes Koshimoto, Bruno Lopes Santos‐Lobato, Ândrea Ribeiro‐dos‐Santos, Giovanna C. Cavalcante · 2023 · Biomedicines
  31. Cognitive Profile in Parkinson’s Disease Dementia Patients with Low versus Normal Cerebrospinal Fluid Amyloid Beta
    Zeynep Tüfekçıoğlu, Johannes Lange, Kenn Freddy Pedersen, Ole‐Bjørn Tysnes, Guido Werner Alves, Murat Emre · 2023 · Dementia and Geriatric Cognitive Disorders Extra
  32. The prevalence of non-troublesome dyskinesia in Parkinson's disease
    Hee Jin Chang, Mihee Jang, Kyung Ah Woo, Jung Hwan Shin, Han‐Joon Kim, Beomseok Jeon · 2024 · Parkinsonism & Related Disorders
  33. Multi-Cue Unit: An independent device and actuator of a wearable system for gait-support in Parkinson patients
    Yan Zhao, Felix Anhalt, Urban M. Fietzek, Lorenzo D’Angelo · 2013 · IEEE International Conference on Microwaves, Communications, Antennas and Electronic Systems (COMCAS)
  34. Rivastigmine in Parkinson??s Disease Dementia1
    M Asif A Siddiqui, Antona J. Wagstaff · 2007 · Drugs & Aging
  35. Rivastigmine for dementia associated with Parkinson’s disease
    John C. Morgan, Kapil D. Sethi · 2005 · Current Neurology and Neuroscience Reports
  36. Le Judo : un sport pour tous
    Romain Rousseau, L. Chiquet, F. Deviere, J. Jouffriault, S. Menard, L. Winkler, A. Frey, Benoit Vesselle · 2019 · Science & Sports
  37. GraphNet-based imaging biomarker model to explain levodopa-induced dyskinesia in Parkinson's disease
    Mansu Kim, Ji Sun Kim, Jinyoung Youn, Hyunjin Park, Jin Whan Cho · 2020 · Computer Methods and Programs in Biomedicine
  38. Parkinson's disease: focus on neuropsychiatric disorders
    Marina Romanovna Nodel · 2020 · Russian Journal of Geriatric Medicine
  39. Peer Mentoring Program for Informal Caregivers of Homebound Individuals With Advanced Parkinson Disease (Share the Care): Protocol for a Single-Center, Crossover Pilot Study
    Jori Erin Fleisher, Faizan Akram, Jeanette Lee, Ellen C. Klostermann, Serena Hess, Erica Myrick, Melissa E. Levin, Bichun Ouyang, Jayne R. Wilkinson, Deborah A. Hall et al. · 2022 · JMIR Research Protocols
  40. THE CORRELATION OF COGNITIVE, EMOTIONAL AND AFFECTIVE DISORDERS IN PATIENTS WITH PARKINSON’S DISEASE
    2016 · The Neurological Journal
  41. Analyses of correct responses and errors on measures of verbal fluency among Parkinson’s disease and essential tremor patients
    Karen Torres, Michael D. Singleton · 2022 · The Clinical Neuropsychologist
  42. Parkinsonian Balance Deficits Quantified Using a Game Industry Board and a Specific Battery of Four Paradigms
    Olivier Darbin, Coral Gubler, Dean K. Naritoku, Daniel Dees, Anthony M. Martino, Elizabeth Adams · 2016 · Frontiers in Human Neuroscience
  43. The Effects of Medical Conditions on Driving Performance: A Literature Review and Synthesis
    Kathy H. Lococo, Loren Staplin, Matthew W. Schultz, Llc TransAnalytics · 2019 · ROSA P
  44. Epidemiology of dystonia, chorea, and athetosis in Al Quseir City (Red Sea Governorate), Egypt
    Reda Badry, Mohamed A. Abdelhamed, Mohamed A. Sayed, Abeer A. Tony, Mohamed Mostafa · 2019 · The Egyptian Journal of Neurology Psychiatry and Neurosurgery
  45. Clinical Features of Parkinson Disease
    W. R. Wayne Martin · 2010 · Health care and disease management
  46. Letter to the Editor: Parkinson's disease and early subthalamotomy
    Jorge Guridi, Jose Angel Obeso · 2015 · Journal of neurosurgery
  47. The mechanism of impaired delayed recall verbal memory function in Parkinson's disease with orthostatic hypotension: a multiple imaging study
    Xiaofan Xue, Anqi Huang, Jingrong Zeng, Haixia Song, Yingqi Xing, Piu Chan, Erhe Xu, Lichun Zhou · 2023 · Frontiers in Neurology
  48. The anti-dyskinetic effect of the clinic-ready mGluR2 positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat
    Judy Shaqfah, Woojin Kang, Fleur Gaudette, Marianne Khalil, Cynthia Kwan, Sébastien Belliveau, Élodie Bourgeois-Cayer, Adjia Hamadjida, Dominique Bédard, Francis Beaudry et al. · 2025 · Naunyn-Schmiedeberg s Archives of Pharmacology
  49. Real-life consequences of cognitive dysfunction in Parkinson's disease
    Kevin R. Kay, Ergun Y. Uc · 2022 · Progress in brain research
  50. The efficacy and safety of medication for treating overactive bladder in patients with Parkinson's disease: a meta-analysis and systematic review of randomized double-blind placebo-controlled trials
    Bo Cheng, Shuangfeng Huang, Qianqian Huang, Zhongbao Zhou, Yiping Bao · 2023 · International Urogynecology Journal
  51. The 5‐HT2A/2C inverse agonist nelotanserin alleviates L‐DOPA‐induced dyskinesia in the MPTP‐lesioned marmoset
    Cynthia Kwan, Imane Frouni, Dominique Bédard, Adjia Hamadjida, Stephen G. Nuara, Jim C. Gourdon, Philippe Huot · 2023 · European Journal of Neuroscience
  52. Effect of the mGlu4 positive allosteric modulator ADX-88178 on parkinsonism, psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset
    Imane Frouni, Cynthia Kwan, Dominique Bédard, Woojin Kang, Adjia Hamadjida, Stephen G. Nuara, Jim C. Gourdon, Philippe Huot · 2023 · Psychopharmacology
  53. Spinal stimulation for unfreezing gait in Parkinson’s disease
    Aviv D. Mizrahi-Kliger, Karunesh Ganguly · 2023 · Nature Medicine
  54. Impact of REM Sleep Behavior and Sleep Talking on Mortality in Parkinson's Disease
    Eemil Partinen, Ari Ylikoski, Mariusz Siemiński, Markku Partinen · 2024 · Cureus
  55. Synchronous monitoring of brain‐heart electrophysiology using heart rate variability coupled with rapid quantitative electroencephalography in orthostatic hypotension patients with α‐synucleinopathies: Rapid prediction of orthostatic hypotension and preliminary exploration of brain stimulation therapy
    Lin Lin, Yingzhe Cheng, Peilin Huang, Jiejun Zhang, Jiahao Zheng, Xiaodong Pan · 2024 · CNS Neuroscience & Therapeutics
  56. An interdisciplinary approach to rehabilitation in Parkinson's disease: case series
    Emilie R. Lowell, Chelsea E. Macpherson, Katya Villarreal‐Cavazos, Anuja Chandrana, Jordanna S. Sevitz, Kelly Veit, Avery E. Dakin, Lori Quinn, Michelle S. Troche · 2024 · Neurodegenerative Disease Management
  57. Recent and on-going trials for the treatment of levodopa-induced dyskinesia: a review of the clinical trial databases
    Jawad Al‐Kassmy, Mohammed Alsalmi, Woojin Kang, Michael Palayew, Philippe Huot · 2025 · Neurodegenerative Disease Management
  58. Role of dysphagia in evaluating Parkinson patients for subthalamic nucleus stimulation: a case report
    Niels Allert, Daniela Kelm, Annika E. Spottke, Volker Arnd Coenen · 2011 · Journal of Neural Transmission
  59. Relación entre el polimorfismo DRD2/ANKK1 y el desarrollo de complicaciones motoras en enfermedad de Parkinson
    Amin Cervantes‐Arriaga, Mayela Rodríguez‐Violante, Paulina González-Latapí, David Davila Ortíz de Montellano, Petra Yescas, Elisa Alonso‐Vilatela · 2014 · Neurología Argentina
  60. Asymmetric responsiveness of disability and health-related quality of life to improvement versus decline in Parkinson’s disease
    Dronacharya Lamichhane, Ann L. Gruber‐Baldini, Stephen G. Reich, Lisa M. Shulman · 2016 · Quality of Life Research
  61. Ex PPN ing how acetylcholine improves gait in Parkinson's disease
    Björn H. Falkenburger · 2017 · Journal of Neurochemistry
  62. The Natural History of Parkinson’s Disease
    Miguel M Coelho, Joaquim José Ferreira · 2017 · Springer eBooks
  63. Medical Treatment of Parkinson Disease
    Stanley Fahn, Joseph J. Jankovic, Mark Hallett, Peter G. Jenner · 2007 · Elsevier eBooks
  64. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset
    Adjia Hamadjida, Stephen G. Nuara, Cynthia Kwan, Imane Frouni, Dominique Bédard, Jim C. Gourdon, Philippe Huot · 2020 · Naunyn-Schmiedeberg s Archives of Pharmacology
  65. Additive effects of mGluR2 positive allosteric modulation, mGluR2 orthosteric stimulation and 5-HT2AR antagonism on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
    Stephen G. Nuara, Jim C. Gourdon, Shawn P. Maddaford, Philippe Huot · 2021 · Naunyn-Schmiedeberg s Archives of Pharmacology
  66. Autoradiographic labelling of 5-HT3 receptors in the hemi-parkinsonian rat brain
    Cynthia Kwan, Catherine Lévesque, Dominique Bédard, Imane Frouni, Jemal M Yesuf, Adjia Hamadjida, Daniel Lévesque, Paul B. S. Clarke, Philippe Huot · 2021 · Neuroscience Research
  67. Cognitive testing in late-stage Parkinson's disease: A critical appraisal of available instruments
    Catarina Severiano e Sousa, Joana Alarcão, Isabel Pavão Martins, Joaquim José Ferreira · 2022 · Applied Neuropsychology Adult
  68. Initiating dopamine agonists rather than levodopa in early Parkinson's disease does not delay the need for deep brain stimulation
    Diana A. Olszewska, Alfonso A. Fasano, Renato P. Munhoz, Carolina Candelaria Ramírez Gómez, Anthony Edward Lang · 2022 · European Journal of Neurology
  69. Chronic H3R activation reduces L-Dopa-induced dyskinesia, normalizes cortical GABA and glutamate levels, and increases striatal dopamine D1R mRNA expression in 6-hydroxydopamine-lesioned male rats
    Alberto Ávila-Luna, Arturo Gálvez-Rosas, Alexander Aguirre-Pérez, Alberto Hidalgo‐Bravo, Alfonso Alfaro-Rodríguez, Camilo Rı́os, José‐Antonio Arias‐Montaño, Antonio Bueno-Nava · 2023 · Psychopharmacology
  70. Psychosis in Parkinson’s Disease and Current Management Trends- an Updated Review of Literature
    Rajib Dutta · 2023 · Journal of Neuroscience and Neurological Disorders
  71. [3H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain
    Imane Frouni, Esther Kim, Judy Shaqfah, Dominique Bédard, Cynthia Kwan, Sébastien Belliveau, Philippe Huot · 2024 · Experimental Brain Research
  72. Zaburzenia autonomiczne w chorobie Parkinsona
    Urszula Fiszer · 2009 · Aktualności Neurologiczne
  73. Phenomenology of Levodopa-Induced Dyskinesia
    Panagiotis Zis, К. Ray Chaudhuri, Michael Samuel · 2014 · Springer eBooks
  74. Depression and dementia in Parkinson's disease.
    Osman Sinanović, Josip Hudić, Sanela Zukić, Almasa Kapidžić, Lejla Zonić, Mirjana Vidović · 2015 · PubMed
  75. Current Problems and Strategies in Motor Rehabilitation for Parkinson’s Disease
    Giovanni Abbruzzese, Elisa Pelosin, Roberta Marchese · 2007 · Springer eBooks
  76. Experimental Models of l-DOPA-Induced Dyskinesia
    Tom H. Johnston, Emma L. Lane · 2011 · International review of neurobiology
  77. Clinical Characteristics of Sleep Disorders in Parkinson's Disease
    Hyun‐Sook Kim, Ji‐Hye Kang, Min-jeong Park, Sang‐Myung Cheon, Kyung Won Park, Jae‐Kwan Cha, Sang-Ho Kim, Jae Woo Kim · 2008 · Journal of the Korean Neurological Association
  78. Parkinson’s Disease and the Claustrum
    Michail E. Kalaitzakis · 2014 · Elsevier eBooks
  79. Parkinsonism and Other Movement Disorders
    Jolyon Meara · 2010 · Elsevier eBooks
  80. Gait Disorders Questionnaire–Promising Tool for Virtual Reality Designing in Patients With Parkinson's Disease
    Zuzana Košutzká, Alice Kušnírová, Michal Hajdúk, Igor Straka, Michal Minár, Peter Valkovič · 2019 · Frontiers in Neurology
  81. Parkinson-Syndrom
    Iris Reuter, Guido Knapp · 2015 · Elsevier eBooks
  82. Recent Advances in Parkinson’s Disease Research: From Pathophysiology to Novel Therapeutic Approaches
    Sujung Yeo · 2025 · Biomedicines
  83. Non-motor symptoms of Parkinson's disease
    Bilal El‐Mansoury, Abdelaati El Khiat, Ayyoub Skaou, Omar El Hiba, Arumugam Radhakrishnan Jayakumar, Youssef Ait Hamdan, Abdelali Bitar, Abdesslam Ferssiwi · 2024 · Elsevier eBooks
  84. Modulation of glycine transporters as a novel therapeutic strategy in neuropsychiatry
    Antonello Pinna, Artur Pałasz · 2025 · Psychopharmacology
  85. The dilemma between milestones of progression versus clinical scales in Parkinson's disease
    Julia C. Greenland, Marta Camacho, Caroline H. Williams‐Gray · 2023 · Handbook of clinical neurology
  86. The effects of chemogenetic targeting of serotonin-projecting pathways on L-DOPA-induced dyskinesia and psychosis in a bilateral rat model of Parkinson’s disease
    Natalie Lipari, Ashley Centner, Shruti Venkatesh, Han Grezenko, Ivette M. Sandoval, Fredric P. Manfredsson, Christopher Bishop · 2024 · Frontiers in Neural Circuits
  87. Sex differences distinguish performance in four object recognition-based memory tasks in the Pink1-/- rat model of Parkinson’s disease
    Aveena M. Desai, Aje Oluwagbohunmi, Mary F. Kritzer · 2025 · Physiology & Behavior
  88. A quick and easy-to-use clinical scale to assess balance in Parkinson's disease
    ABRAHAM N. LIEBERMAN, Dhanani, Dhall, Pan Pan · 2012 · Journal of Parkinsonism and Restless Legs Syndrome
  89. Conformational preference and mechanism of decarboxylation of levodopa. A quantum dynamics/quantum mechanics study
    Shaaban A. K. Elroby, Ashour A. Ahmed, Rifaat Hilal · 2013 · International Journal of Quantum Chemistry
  90. What light have resting state fMRI studies shed on cognition and mood in Parkinson’s disease?
    Sophie L. YorkWilliams, Kathleen L. Poston · 2014 · Journal of Clinical Movement Disorders
  91. Adenosine A2A Receptor Gene Knockout Prevents l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia by Downregulation of Striatal GAD67 in 6-OHDA-Lesioned Parkinson’s Mice
    Su-bing Yin, Xiaoguang Zhang, Shuang Chen, Wen-ting Yang, Xia-wei Zheng, Guo‐qing Zheng · 2017 · Frontiers in Neurology
  92. Benefits of Levodopa-Carbidopa Intestinal Gel Infusion in Patients with Parkinson’s Disease Experiencing Gait Dysfunction Following Subthalamic Deep Brain Stimulation
    Thomas Edmund Kimber, YiZhong Zhuang, Philip Douglas Thompson · 2019 · Journal of Movement Disorders
  93. Evaluation of the Impact of Integrated Care and Self-Management After Deep Brain Stimulation in Parkinson’s Disease
    Deepa Dash, Diane Côté, Jennifer Conway, David Grimes, Tiago Mestre · 2022 · Journal of Parkinson s Disease
  94. Development of Clinical Milestones in Parkinson’s Disease After Bilateral Subthalamic Deep Brain Stimulation
    Jed Noel Ong, Jung Hwan Shin, Seung Ho Jeon, Chan Young Lee, Han‐Joon Kim, Sun Ha Paek, Beomseok Jeon · 2022 · Journal of Movement Disorders
  95. Dietary interventions in Parkinson’s disease: An update
    Sujith Pavan, Arvind Prabhu, Sankar Prasad Gorthi, Vignesh Shetty, Vidya Rajesh, Asha Hegde, Mamatha Ballal · 2022 · Biomedicine
  96. 5-HT 1A Agonists for levodopa-induced Dyskinesia in Parkinson’s Disease
    Jawad Al‐Kassmy, Christine Sun, Philippe Huot · 2023 · Neurodegenerative Disease Management
  97. Neurocognitive Impairment and Social Cognition in Parkinson’s Disease Patients
    Triantafyllos K. Doskas, Κonstantinos Vadikolias, Konstantinos T. Ntoskas, George D. Vavougios, Dimitrios Tsiptsios, Polyxeni Stamati, Ioannis Liampas, Vasileios Siokas, Lambros Messinis, Grigorios Nasios et al. · 2024 · Neurology International
  98. Positive allosteric mGluR2 modulation with BINA alleviates dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
    Woojin Kang, Imane Frouni, Dominique Bédard, Cynthia Kwan, Adjia Hamadjida, Stephen G. Nuara, Jim C. Gourdon, Philippe Huot · 2024 · Naunyn-Schmiedeberg s Archives of Pharmacology
  99. Validity and reliability of the Italian version of the short Parkinson's evaluation scale (SPES/SCOPA)
    Stefan Robert Pisaltu, Ilaria Ruotolo, Giovanni Sellitto, Anna Berardi, Rachele Simeon, Giovanni Fabbrini, Giovanni Galeoto · 2024 · Heliyon
  100. Effect of the mGlu 2 positive allosteric modulator biphenyl‐indanone A as a monotherapy and as adjunct to a low dose of L‐DOPA in the MPTP‐lesioned marmoset
    Woojin Kang, Imane Frouni, Cynthia Kwan, Dominique Bédard, Stephen G. Nuara, Adjia Hamadjida, Jim C. Gourdon, Philippe Huot · 2024 · European Journal of Neuroscience